More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this trial comes along directing us back to basics. 

estenosis aórtica moderada

In patients with symptomatic aortic stenosis, peaking mortality will clearly justify intervention. But what is the case when there are no symptoms? According to this recent analysis published in JAMA, asymptomatic moderate aortic stenosis does not bring about higher mortality when compared against mild AS

Therefore, we will end up going back to the traditional approach based on symptoms (look closely and wait) when it comes to moderate AS. 

However, the new trend that resorts to prognostic factors to find patients that will benefit from an early intervention must continue

In this study, mortality observed in mild AS was no different from expected mortality in the general population. Patients with moderate AS did show higher mortality risk vs. the general population (though still far from that of severe AS patients). 

This slightly more elevated mortality in moderate AS patients was found in symptomatic patients. Why would moderate AS present with symptoms? The answer to this question is that stenosis might have never been properly assessed and that there might be patients requiring additional markers.


Read also: STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients.


At this point, we might be able to combine the traditional approach with the new trend: waiting for symptoms to show works for most patients; however, some patients (the number still unknown) will benefit from additional assessment and, perhaps, early intervention. 

The VALVENOR included 2703 ambulatory patients with AS. Stenosis degree was defined according to peak velocity in transthoracic ECG, resulting in 42.7% mild AS (2.5 to 2.9 m/sec velocity), 41.5% moderate AS (3 to 3.9 m/sec velocity) and 15.8% severe AS (≥4 m/sec peak velocity).

There were no differences in the rest of baseline characteristics.


Read also: The FDA Approves a Third Device in the TAVR Race.


During followup, 775 patients showed stenosis progress by ECG: 45.2% showed mild to moderate progress, 7.7% mild to severe and 47.1% moderate to severe.

634 of 775 patients who progressed were intervened. Non-intervention was decided upon patient refusal or death while waiting for the procedure. 

Our efforts should aim at finding patients with moderate AS who will progress faster than expected or will die of heart disease (cardiac failure or sudden death). 

Original Title: Association of mortality with aortic stenosis severity in outpatients: results from the VALVENOR study.

Reference: Coisne A et al. JAMA Cardiol. 2021 Sep 29. Online ahead of print. doi: 10.1001/jamacardio.2021.3718. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...